Stifel reiterates Alumis stock rating on psoriasis trial data By Investing.com

Stifel reiterated a Buy on Alumis and a $44 price target, implying meaningful upside from the current $24.63 share price after the company’s first-quarter 2026 update and Phase 3 envudeucitinib data. The drug’s PASI responses continued to deepen through week 24, and analysts across Wall Street remain broadly positive with targets ranging from $25 to $55. Near-term focus is on Phase 2b systemic lupus erythematosus data in Q3 2026 and an NDA filing now expected in Q4 2026.

Analysis

The market is treating this as a single-asset de-risking event, but the real takeaway is that the bar for next-gen TYK2 differentiation just moved higher, not lower. If Alumis can preserve efficacy with tolerability through the regulatory process, the franchise becomes less about psoriasis share capture and more about optionality in adjacent immune indications where oral convenience matters and payer friction is lower than in crowded biologics. That raises the probability of partnership interest, but also means valuation will increasingly hinge on broad label breadth rather than one dermatology readout.

The second-order winner is any company with a credible oral immunology platform and clean late-stage data; the loser is the premium assigned to “me-too with better safety” stories in TYK2. JNJ is the clearest indirect pressure point because even a modestly superior oral profile can force a re-rating of its internal immunology economics and future lifecycle assumptions, especially if prescribers start anchoring to convenience plus efficacy rather than class novelty. More broadly, positive SLE data would expand the addressable market enough to justify strategic bids, which means the stock could gap on data before the street fully adjusts its peak-sales model.

The key risk is timing mismatch: the next visible catalyst is months away, while the stock has already rerated aggressively, so the easy money is likely gone unless the lupus data materially exceeds the current efficacy bar. Any safety signal, slower NDA process, or partner hesitation would hit disproportionately because the equity is now trading on future optionality rather than present fundamentals. In that setup, the asymmetry shifts from long only to event-driven, with the downside being a multiple compression rather than a complete thesis break.

Consensus appears to be underestimating how binary the upcoming lupus readout is for the partnership narrative. If efficacy merely matches the class, the market will likely cap upside and focus on commercialization risk; if it beats the incumbent standard convincingly, ALMS can trade like a strategic asset rather than a standalone small-cap launch story. That makes the current setup more attractive as a conditional trade than as a fresh outright long.

Key Decisions for Investors

• Buy ALMS only as a catalyst trade into the Q3 2026 SLE data, not as a core hold; size at 1/2 normal risk and trim into any pre-data strength given elevated expectation risk.
• Pair trade: long ALMS / short JNJ into the next immunology sector window if you want to express TYK2 share shift; thesis works only if ALMS data supports premium oral differentiation.
• If options liquidity is sufficient, structure a call spread in ALMS expiring after the lupus readout to capture upside while capping premium bleed; best risk/reward if implied vol stays below realized event vol.
• For investors already long ALMS, hedge with a stop-loss discipline around any regulatory or safety-driven drawdown; the stock’s rerating leaves little margin for a mid-teens multiple reset.
• Monitor any partnership or BD headline from now through Q3 2026; a credible ex-U.S. deal would be a fast catalyst for another 15-25% rerating, while silence would argue for de-risking.